Can a second dose of smart drugs shrink tumors again?

NCT ID NCT06649331

First seen Nov 19, 2025 · Last updated Jun 14, 2026 · Updated 27 times

Summary

This study looks at whether giving a second course of antibody-drug conjugates (ADCs) can safely shrink tumors in people with advanced breast cancer who have already received these drugs. About 160 adults with metastatic breast cancer will receive the same or a different ADC and be monitored for response and side effects. The goal is to see if rechallenging with ADCs offers meaningful disease control when standard options are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Breast cancer institute of Fudan University Cancer Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.